The role of vasoactive intestinal peptide in pulmonary diseases
Copyright © 2023 Elsevier Inc. All rights reserved..
Vasoactive intestinal peptide (VIP) is an abundant neurotransmitter in the lungs and other organs. Its discovery dates back to 1970. And VIP gains attention again due to the potential application in COVID-19 after a research wave in the 1980s and 1990s. The diverse biological impacts of VIP extend beyond its usage in COVID-19 treatment, encompassing its involvement in various pulmonary and systemic disorders. This review centers on the function of VIP in various lung diseases, such as pulmonary arterial hypertension, chronic obstructive pulmonary disease, asthma, cystic fibrosis, acute lung injury/acute respiratory distress syndrome, pulmonary fibrosis, and lung tumors. This review also outlines two main limitations of VIP as a potential medication and gathers information on extended-release formulations and VIP analogues.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:332 |
|---|---|
| Enthalten in: |
Life sciences - 332(2023) vom: 01. Nov., Seite 122121 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhong, Hong-Lin [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 11.10.2023 Date Revised 11.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.lfs.2023.122121 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362392110 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362392110 | ||
| 003 | DE-627 | ||
| 005 | 20231226091137.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lfs.2023.122121 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362392110 | ||
| 035 | |a (NLM)37742737 | ||
| 035 | |a (PII)S0024-3205(23)00756-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhong, Hong-Lin |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The role of vasoactive intestinal peptide in pulmonary diseases |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.10.2023 | ||
| 500 | |a Date Revised 11.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Vasoactive intestinal peptide (VIP) is an abundant neurotransmitter in the lungs and other organs. Its discovery dates back to 1970. And VIP gains attention again due to the potential application in COVID-19 after a research wave in the 1980s and 1990s. The diverse biological impacts of VIP extend beyond its usage in COVID-19 treatment, encompassing its involvement in various pulmonary and systemic disorders. This review centers on the function of VIP in various lung diseases, such as pulmonary arterial hypertension, chronic obstructive pulmonary disease, asthma, cystic fibrosis, acute lung injury/acute respiratory distress syndrome, pulmonary fibrosis, and lung tumors. This review also outlines two main limitations of VIP as a potential medication and gathers information on extended-release formulations and VIP analogues | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Acute respiratory distress syndrome | |
| 650 | 4 | |a Chronic obstructive pulmonary disease | |
| 650 | 4 | |a Lung cancer | |
| 650 | 4 | |a Pulmonary arterial hypertension | |
| 650 | 4 | |a Vasoactive intestinal peptide | |
| 650 | 7 | |a Vasoactive Intestinal Peptide |2 NLM | |
| 650 | 7 | |a 37221-79-7 |2 NLM | |
| 700 | 1 | |a Li, Pei-Ze |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Di |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Cha-Xiang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Life sciences |d 1965 |g 332(2023) vom: 01. Nov., Seite 122121 |w (DE-627)NLM000007579 |x 1879-0631 |7 nnns |
| 773 | 1 | 8 | |g volume:332 |g year:2023 |g day:01 |g month:11 |g pages:122121 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lfs.2023.122121 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 332 |j 2023 |b 01 |c 11 |h 122121 | ||